Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

被引：0
|
作者：
Kohei Shitara
Hiroki Hara
Takaki Yoshikawa
Kazumasa Fujitani
Tomohiro Nishina
Ayumu Hosokawa
Takashi Asakawa
Satoe Kawakami
Kei Muro
机构：
[1] National Cancer Center Hospital East,Gastroenterology and Gastrointestinal Oncology
[2] Saitama Cancer Center,Department of Gastroenterology
[3] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[4] National Cancer Center Hospital,Department of Gastric Surgery
[5] Osaka General Medical Center,Department of Surgery
[6] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[7] University of Toyama,Department of Gastroenterology and Hematology, Faculty of Medicine
[8] University of Miyazaki Hospital,Department of Clinical Oncology
[9] Chugai Pharmaceutical Co.,Clinical Information and Intelligence Department
[10] Ltd,Clinical Science & Strategy Department
[11] Chugai Pharmaceutical Co.,Department of Clinical Oncology
[12] Ltd,undefined
[13] Aichi Cancer Center Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Pertuzumab; Trastuzumab; Metastatic gastric cancer; Metastatic gastroesophageal junction cancer; Japanese subgroup analysis; Phase III;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 311
页数：10
相关论文
共 50 条
  • [1] Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial
    Shitara, Kohei
    Hara, Hiroki
    Yoshikawa, Takaki
    Fujitani, Kazumasa
    Nishina, Tomohiro
    Hosokawa, Ayumu
    Asakawa, Takashi
    Kawakami, Satoe
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (02) : 301 - 311
  • [2] Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
    Liu, Tianshu
    Qin, Yanru
    Li, Jin
    Xu, Ruihua
    Xu, Jianming
    Yang, Shujun
    Qin, Shukui
    Bai, Yuxian
    Wu, Changping
    Mao, Yixiang
    Wu, Haiyan
    Ge, Yilin
    Shen, Lin
    CANCER COMMUNICATIONS, 2019, 39
  • [3] Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
    Tabernero, Josep
    Hoff, Paulo M.
    Shen, Lin
    Ohtsu, Atsushi
    Shah, Manish A.
    Siddiqui, Asna
    Heeson, Sarah
    Kiermaier, Astrid
    Macharia, Harrison
    Restuccia, Eleonora
    Kang, Yoon-Koo
    GASTRIC CANCER, 2023, 26 (01) : 123 - 131
  • [4] Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
    Josep Tabernero
    Paulo M. Hoff
    Lin Shen
    Atsushi Ohtsu
    Manish A. Shah
    Asna Siddiqui
    Sarah Heeson
    Astrid Kiermaier
    Harrison Macharia
    Eleonora Restuccia
    Yoon-Koo Kang
    Gastric Cancer, 2023, 26 : 123 - 131
  • [5] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    Sawaki, Akira
    Ohashi, Yasuo
    Omuro, Yasushi
    Satoh, Taroh
    Hamamoto, Yasuo
    Boku, Narikazu
    Miyata, Yoshinori
    Takiuchi, Hiroya
    Yamaguchi, Kensei
    Sasaki, Yasutsuna
    Nishina, Tomohiro
    Satoh, Atsushi
    Baba, Eishi
    Tamura, Takao
    Abe, Takashi
    Hatake, Kiyohiko
    Ohtsu, Atsushi
    GASTRIC CANCER, 2012, 15 (03) : 313 - 322
  • [6] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
    Akira Sawaki
    Yasuo Ohashi
    Yasushi Omuro
    Taroh Satoh
    Yasuo Hamamoto
    Narikazu Boku
    Yoshinori Miyata
    Hiroya Takiuchi
    Kensei Yamaguchi
    Yasutsuna Sasaki
    Tomohiro Nishina
    Atsushi Satoh
    Eishi Baba
    Takao Tamura
    Takashi Abe
    Kiyohiko Hatake
    Atsushi Ohtsu
    Gastric Cancer, 2012, 15 : 313 - 322
  • [7] Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB)
    Tabernero, Josep
    Hoff, Paulo Marcelo
    Shen, Lin
    Ohtsu, Atsushi
    Yu, Ron
    Eng-Wong, Jennifer
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
    Whitney P. Kirschbrown
    Bei Wang
    Ihsan Nijem
    Atsushi Ohtsu
    Paulo M. Hoff
    Manish A. Shah
    Lin Shen
    Yoon-Koo Kang
    Maria Alsina
    Sandhya Girish
    Amit Garg
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 539 - 550
  • [9] Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
    Kirschbrown, Whitney P.
    Wang, Bei
    Nijem, Ihsan
    Ohtsu, Atsushi
    Hoff, Paulo M.
    Shah, Manish A.
    Shen, Lin
    Kang, Yoon-Koo
    Alsina, Maria
    Girish, Sandhya
    Garg, Amit
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (03) : 539 - 550
  • [10] Trastuzumab a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer
    Lordick, Florian
    FUTURE ONCOLOGY, 2011, 7 (02) : 187 - 199
12345